These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Drugs in phase I and phase II clinical trials for systemic sclerosis. Chung MP; Chung L Expert Opin Investig Drugs; 2020 Apr; 29(4):349-362. PubMed ID: 32178544 [No Abstract] [Full Text] [Related]
7. Advances in biological and targeted therapies for systemic sclerosis. Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674 [TBL] [Abstract][Full Text] [Related]
8. [B cell abnormalities and therapeutic strategies in systemic sclerosis]. Yoshizaki A Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935 [TBL] [Abstract][Full Text] [Related]
9. The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. Benvenuti F; Zanatta E; Avouac J; Müller-Ladner U; Cozzi F; Hoffmann-Vold AM; Gabrielli A; Distler O; Matucci-Cerinic M; Allanore Y; Doria A Expert Rev Clin Immunol; 2020 Nov; 16(11):1065-1074. PubMed ID: 33076716 [TBL] [Abstract][Full Text] [Related]
10. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. McMahan ZH; Volkmann ER Expert Opin Pharmacother; 2020 Nov; 21(16):2041-2056. PubMed ID: 32674612 [TBL] [Abstract][Full Text] [Related]
11. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy. Distler O; Cozzio A Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237 [TBL] [Abstract][Full Text] [Related]
13. Emerging targeted therapies in scleroderma lung and skin fibrosis. Maurer B; Distler O Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265 [TBL] [Abstract][Full Text] [Related]
14. Clinical Trial Design Issues in Systemic Sclerosis: an Update. Gordon JK; Domsic RT Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381 [TBL] [Abstract][Full Text] [Related]
15. Emerging drugs and therapeutics for systemic sclerosis. Lee JJ; Pope JE Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423 [TBL] [Abstract][Full Text] [Related]
16. Preclinical and translational research to discover potentially effective antifibrotic therapies in systemic sclerosis. Jordan S; Chung J; Distler O Curr Opin Rheumatol; 2013 Nov; 25(6):679-85. PubMed ID: 24047603 [TBL] [Abstract][Full Text] [Related]
17. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years. Campochiaro C; Allanore Y Arthritis Res Ther; 2021 Jun; 23(1):155. PubMed ID: 34074331 [TBL] [Abstract][Full Text] [Related]
18. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis. Farina N; Campochiaro C; Lescoat A; Benanti G; De Luca G; Khanna D; Dagna L; Matucci-Cerinic M Expert Rev Clin Immunol; 2023; 19(9):1131-1142. PubMed ID: 37366065 [TBL] [Abstract][Full Text] [Related]
19. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. White B; Bauer EA; Goldsmith LA; Hochberg MC; Katz LM; Korn JH; Lachenbruch PA; LeRoy EC; Mitrane MP; Paulus HE Arthritis Rheum; 1995 Mar; 38(3):351-60. PubMed ID: 7880189 [TBL] [Abstract][Full Text] [Related]
20. The evolving pharmacotherapy of pulmonary fibrosis. Lota HK; Wells AU Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]